@article{article_1106134, title={Multiple Myeloma; Experience of a Center}, journal={International Archives of Medical Research}, volume={14}, pages={14–20}, year={2022}, DOI={10.56484/iamr.1106134}, author={Demircan, Vehbi and Yiğit, Ercan and Karakuş, Abdullah and Ayyıldız, Orhan}, keywords={Myelom, New agents, Transplantation, Myelom, New agents, Transplantation}, abstract={<p>Objective: Demographic characteristics, laboratory parameters, applied treatments, and treatment responses of patients diagnosed with multiple myeloma (MM) at the time of diagnosis vary between communities. We aimed to investigate this data of Multiple Myeloma patients and compare it with literature data. </p> <p>
Material Method: In this study, we retrospectively examined data of 272 patients diagnosed with MM between January 1st, 2010, and January 31st, 2019 in Dicle University Faculty of Medicine Internal Medicine Hematology Clinic. At the time of diagnosis, general characteristics, laboratory values, treatment options, treatment responses, mean and median survival times, and causes of mortality of the participated patients in the study were investigated. </p> <p>Results: We found that 124 (45.6%) patients had IgG, 50 patients had (18.4%) ıgA, 59 patients had (21.7%) light chain, 21 patients had (7.7%) plasmacytoma, four patients had (1.5%) ıgM, three patients had (1.1%) plasma cell leukemia, and 11 patients had (4%) non-secretory myeloma. 77 patients underwent autologous hematopoietic stem cell transplantation (AHSCT). The average life expectancy in patients with AHSCTwas 68 months, while in patients without AHSCT, this period was determined as 42 months (p<0.001). </p> <p>
Conclusion: We see that treatment response rates and average survival times increase with the introduction of new agents. </p>}, number={1}, publisher={Veysi AKPOLAT}, organization={sponsorsuz kendi çalışmamız}